Special Issue

Lipid Metabolism Regulation and Obesity Treatment

Message from the Guest Editors

Sadly, these last few years will remain infamous for the COVID-19 pandemic, but for decades, another well-known pandemic has been continuing to expand, not sparing any age group: obesity. Obesity can be defined as a state of altered metabolic homeostasis which is accompanied by atherogenic dyslipidemia, insulin resistance, and arterial hypertension. For these reasons, the growing prevalence of obesity will certainly contribute to the burden of cardiovascular disease. Furthermore, obesity and dyslipidemia are the main features of metabolic syndrome, and both can present with adipose tissue dysfunction, involved in the pathogenetic mechanisms underlying this syndrome. In this Special Issue, we would like to focus on the emerging understanding of biochemical and molecular mechanisms involved in inflammation, atherogenesis, and lipid metabolic dysfunction in obesity. Other interesting and innovative topics related to obesity treatment will be welcome.

Guest Editors

Dr. Diego Moriconi
Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy

Dr. Tiziana Sampietro
Toscana Gabriele Monasterio Foundation, Lipoapheresis Unit - Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias, I-56124 Pisa, Italy

Deadline for manuscript submissions

closed (31 December 2022)

Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed

mdpi.com/si/132235

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/metabolites



Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed

mdpi.com/journal/metabolites

MDPI

About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo
Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).